Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewCritical appraisal of trastuzumab in treatment of advanced stomach cancerPhase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerGastric cancer: The times they are a-changin'Molecular classification of gastric cancer: Towards a pathway-driven targeted therapyNovel immunotherapeutic strategies of gastric cancer treatmentTargeting receptor tyrosine kinases in gastric cancerMolecular targeted therapy for the treatment of gastric cancerCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancerRandomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Neoadjuvant treatment of esophageal cancer.Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Targeted therapies for gastric cancer: current status.Molecular targeting to treat gastric cancer.Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell lineRecent advances in chemotherapy for advanced gastric cancerA multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.DNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapySynchronous oesophagectomy and hepatic resection for metastatic oesophageal cancer: report of a caseTreatment options in patients with metastatic gastric cancer: current status and future perspectivesCurrent status of novel agents in advanced gastroesophageal adenocarcinoma.Targeting metastatic upper gastrointestinal adenocarcinomasA phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junctionRefining docetaxel-containing therapy for gastric cancer.EPMA position paper in cancer: current overview and future perspectives.Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.Gastric cancer and the epoch of immunotherapy approachesTargeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinomaLocally advanced cancer of the esophagus, current treatment strategies, and future directionsTargeted therapy for esophagogastric cancers: a reviewGastric carcinoma in China: Current status and future perspectives (Review)
P2860
Q21198850-FB2DB2FE-44CB-4C31-9F83-9EA2531B934BQ24604411-1C435781-5EED-4FDB-88FB-CDD721095E67Q24649684-084EE81E-605F-47DD-83C0-9FEF87EFEE72Q26776195-C2126F0F-08C7-4427-B98A-57582DC11CDEQ26798420-AF7140F6-0D42-42A9-9CE8-193131379205Q27011232-4C555D25-A404-43DF-91A9-04B901ACE102Q27013050-D400645A-C72A-438A-B79C-102A2D28472CQ28072433-10FFE142-DD86-46BA-9112-8CB7ED4EC196Q28081844-5529AC66-ABF7-446E-B71A-5FD9011051BDQ28477038-FE180868-7758-43A3-BAA4-723D86056DB2Q33380002-C83E93EA-C746-4279-9799-BC61A50A1BB7Q33387432-957A0CFA-82ED-4244-9F75-14636062FB35Q33389519-12C9F4EF-8388-4005-8DA6-35450CE0CC5EQ33658636-CE82D04B-71CA-4ED8-AFD7-D2F65B014F88Q33746766-8454F514-3B6F-4BA7-B42F-CDD67D36EFBBQ33932460-9CEF56A3-4457-4AE6-A160-9ED139458121Q34063710-1736ABCB-925C-4E15-9951-CB1023D0B3C7Q34084724-B49AEC96-81ED-4132-87CD-E129F5B089EFQ34094855-919C5EC2-00A1-487E-AAB9-CA45A7AF2806Q34205672-BA4F51C5-4B55-4924-8C2B-B77B5F5CA440Q34326593-1FA282EE-408B-4864-9A58-5844D88349F3Q34366588-959E8DC3-EDD6-435F-AA46-20B43EEC3E8FQ34389753-1227BA83-7682-4DE0-A8F2-68C847104A0EQ34403664-CE7B4545-BFF7-43FF-9AA3-DCA5738CC5BBQ34413771-F8D6DB2B-CA47-4F8F-8E99-CBD56B2DBD18Q34541316-AAC76D8E-6298-40FF-A9EF-D3618E5E2DF7Q34661367-4D204C49-99AF-4DE7-AC9B-1D684CFCF095Q34962039-15BE5E4D-3297-458D-AE6A-D67BE88997DDQ35000785-CBE85FE4-E969-4ED7-8D4B-84CB24219871Q35050662-8F7B88E4-AFB3-4C7E-89E2-1FD9C0BFB92CQ35208151-F1ED53E8-B82B-413E-BAB9-4C88FAF9C7ADQ35445166-EF547E79-E386-47A6-8A42-5BB2CFC2DAD5Q35532215-6BFD8016-E2E4-4E73-BFA8-2F6A3A6150CCQ35565614-93381CDF-C928-43B2-BFB5-E9E15D752896Q35625349-3306BE39-051C-41B9-8416-34A10F62EECAQ35863874-2BFF684A-7032-455E-ADFE-1F63D7341A28Q35948006-BA235D3F-E661-4F1F-A5E1-FFD97BEC3BCCQ35985417-B609FFAE-F1EB-4912-83D6-818B41B31A97Q36039645-E020337D-30FF-44FE-8700-B8A6513F219CQ36216823-9CDAF1CD-37FD-4ED7-9029-D14D20D3C66F
P2860
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Phase II study of cetuximab in ...... enocarcinoma (FOLCETUX study).
@en
Phase II study of cetuximab in ...... hageal junction adenocarcinoma
@nl
type
label
Phase II study of cetuximab in ...... enocarcinoma (FOLCETUX study).
@en
Phase II study of cetuximab in ...... hageal junction adenocarcinoma
@nl
prefLabel
Phase II study of cetuximab in ...... enocarcinoma (FOLCETUX study).
@en
Phase II study of cetuximab in ...... hageal junction adenocarcinoma
@nl
P2093
P50
P921
P356
P1433
P1476
Phase II study of cetuximab in ...... enocarcinoma (FOLCETUX study).
@en
P2093
A A Martoni
C Funaioli
C Longobardi
F Di Fabio
F L Rojas Llimpe
L Giannetta
S Giaquinta
P304
P356
10.1093/ANNONC/MDL459
P577
2006-12-12T00:00:00Z